SECAUCUS, N.J., March 20, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic information services, today announced it has completed its previously announced acquisition of select assets of Northern Light Laboratory, the outreach laboratory services business of Northern Light Health, a large integrated healthcare system in Maine.
The collaboration between the two parties is expected to enable physicians and patients throughout Maine to benefit from access to Quest's industry-leading and highly innovative test menu, network of patient access sites throughout the state, broad health plan coverage, and lower out-of-pocket costs for many services. Quest's state-of-the-art laboratory in Marlborough, Mass. will provide the majority of advanced and routine clinical testing services for physicians and patients previously served by Northern Light Laboratory.
In addition, Quest now provides professional laboratory management services for nine of Northern Light Health's hospital laboratories, along with its cancer center laboratory at Northern Light Cancer Care in Brewer, Maine. Financial details of the transaction were not disclosed.
Quest provides a complete portfolio of services to empower health systems and hospitals to improve the quality, innovation and insights of their diagnostic laboratory services, elevate the patient experience and lower costs for more accessible—and affordable—care. For more information, visit Hospitals & Health Systems | Quest Diagnostics.
About Quest Diagnostics
Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our approximately 50,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. www.QuestDiagnostics.com.
Last Trade: | US$160.36 |
Daily Change: | -0.96 -0.60 |
Daily Volume: | 475 |
Market Cap: | US$17.900B |
October 23, 2024 October 22, 2024 October 15, 2024 September 18, 2024 August 26, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB